Study of renal parameter changes by intraperitoneal injection of amikacin and cefotaxime in albino rats

Suhail Ahmad¹, Roquiya Begum², Manish Kumar³*

INTRODUCTION

The use of a broad spectrum anti-microbial singly or in combination is increasing day by day in clinical practice for a wide range of conditions. It is being used in adults, children as well as in elderly.

Amikacin (an aminoglycoside) and cefotaxime (a third-generation cephalosporin) use have shown resurgence in the field of medicine. All three are mainly excreted by renal mechanisms. Various studies have reported that these drugs have the ability to influence the structure and/or function of kidneys.

ABSTRACT

Background: Amikacin and cefotaxime are excreted by renal mechanisms and have ability to influence the structure and/or function of kidneys. In the present study, an attempt has been made to assess the nephrotoxic effects of amikacin, cefotaxime, and their combination.

Methods: A total of 10 albino rats (180-210 g) were included in each of four groups. Group A (control group) received i.p. 2 ml/kg/day of normal saline, Group B received i.p. 15 mg/kg/day of amikacin, Group C received i.p. 100 mg/kg/day of cefotaxime, and Group D received i.p. amikacin and cefotaxime daily for 4 weeks. Blood urea nitrogen (BUN) and serum creatinine were estimated at 1st, 14th, 28th day during i.p. administration then at 6th and 18th month during follow-up. Data obtained were expressed as mean±standard deviation and analyzed using the analysis of variance.

Results: At 1st day, 14th day, 28th day, 6th month, 18th month, mean blood urea and serum creatinine in Group A were 20.37±0.08, 20.42±0.10, 20.48±0.09, 20.38±0.10, 20.45±0.07 and 0.50±0.07, 0.49±0.09, 0.48±0.075, 0.49±0.034, and 0.48±0.045, respectively; in Group B were 20.31±0.06, 24.08±0.50, 25.68±0.57, 22.60±0.09, 21.52±0.36 and 0.50±0.07, 0.65±0.093, 0.78±0.097, 0.63±0.08, 0.56±0.063, respectively; in Group C were 20.11±0.06, 23.84±0.08, 25.11±0.46, 22.50±0.78, 21.14±0.65 and 0.52±0.073, 0.69±0.063, 0.83±0.081, 0.69±0.062, 0.57±0.52, respectively; in Group D were 20.70±1.55, 26.32±1.1, 29.90±0.98, 26.05±1.6, 23.44±1.0 and 0.53±0.045, 0.90±0.084, 1.04±0.14, 0.91±0.045, 0.89±0.048 respectively. Mean BUN and serum creatinine were normal in Group A, but increase was highly significant in Group B, C, and D during drug administration but decreased during follow-up. In Group D, the mean level remained above the normal range till 18th month.

Conclusions: Rise in BUN and serum creatinine was highly significant when the amikacin was combined with cefotaxime during i.p. administration as well as during follow-up. It concluded that these drug combinations may be harmful to the kidney, and gradually, it can lead to permanent renal damage.

Keywords: Amikacin, Cefotaxime, Blood urea nitrogen, Serum creatinine

Received: 04 January 2015
Accepted: 17 February 2015

*Correspondence to:
Dr. Manish Kumar,
Email: manu072@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
filtration and attains high concentration in urine. Significant accumulation occurs in the renal cortex, and its excretion is directly proportional to creatinine clearance. Dosage adjustments are required in renal insufficiency including normal aging to avoid accumulation of drug and toxicity. Single daily dosing is preferred than twice or thrice daily dosing schedules. Risk of adverse effect is more if high dose, prolonged duration, and several doses are given. In humans, aminoglycosides are administered intramuscular or intravenous (IV). Its serum half-life is 2-5 hrs.

Nephrotoxicity is a form of acute tubular necrosis and inability to concentrate the urine. The damage occurs after 5-7 days of therapy. Urine contains protein and tubular cell casts. Glomerular filtration rate is reduced, elevation of creatinine, and concentration of urea in plasma occurs. Same effect has been seen by Luft and Kleit, Luft et al. A part from above-mentioned nephrotoxicity, anuria, and acute tubular necrosis associated with amikacin and cephalosporin has been described by Bobrow et al., Schultze et al., Fillastre et al., and Noone et al. Cefotaxime and amikacin concurrently used may cause nephrotoxicity in elderly patients.

Effects of amikacin on rats have been illustrated by Cohen et al. and according to them amikacin stimulates especially the organic transport system and that this effect may represent an early functional correlate of amikacin nephrotoxicity. Nephrotoxicity of amikacin in association to the proximal renal tubule has also been reported by Kosek et al. Cephalosporins are broad spectrum antibiotic. Its mechanism of action is by inhibition of bacterial cell wall synthesis like penicillin. It is inactivated by cephalosporinase enzyme. Cefotaxime, a third-generation cephalosporin, has extended Gram-negative and Gram-positive coverage with the ability to cross the blood-brain barrier. It is also active against citrobacter, serratia, providencia, B-lactamase producing strains of hemophilus and neisseria.

Cephalosporins are excreted unchanged in the urine. Many are actively secreted by the renal tubule, a process which can be blocked by probenecid. Hence, dose should be reduced in patients with poor renal function.

In United States and Japan, cephalosporins are the antibiotic most often prescribed to hospital patients. In Japan, they are frequently used for prophylaxis of infections after abdominal and pelvic surgery and operations entailing a foreign body implant as in cardiac and orthopedic surgery.

In India, cephalosporins have high potential for application in special circumstances such as Gram-positive infections resistant to penicillin or in infections by Escherichia coli, Klebsiella and Aerobacter, Gram-negative fulminating septicemia, meningitis, and endocarditis. Cephalosporin injection with amikacin is recommended for initial emergency treatment.

It is orally or parenterally administered. After absorption, it is bound to plasma proteins (70-80%) and found in all the body secretions e.g. bile and cerebrospinal fluid. Excretion by the kidney by glomerular filtration and tubular secretion is reported.

Renal tubular necrosis has followed after administration of cefotaxime in dosage >4 g/day i.e. more common in patients with pre-existing renal disorder. Cephalosporin and amikacin concurrently used may cause nephrotoxicity in elderly patients over 60 years of age. The dosage should be moderately reduced in patients with impaired renal function. The nephrotoxicity of cephalosporin has also been demonstrated by Barza, 1978. Elimination of cephalosporin has been illustrated by Child and Dodds, 1966. Cephalosporin produces proximal renal tubular necrosis in a number of laboratory animals. Rabbits and other animal species are more sensitive to cephalosporin nephrotoxicity.

Elderly patients are more sensitive to drug combination causing nephrotoxicity e.g. patient with shock, dehydration, pre-existing renal diseases or oliguria. Its nephrotoxicity has also been reported by several workers. Thus, an effort has been made in this study to quantify the nephrotoxic effects of amikacin, cefotaxime, and their combination by measuring its effect on renal parameters in the experimental animals in standard laboratory using perfect technique and under optimum conditions.

METHODS

This study was done in the Department of Pharmacology, Patna Medical College and Hospital, Patna. The study protocol was approved by Institutional Animal Ethics Committee. The experiment was performed on albino rats weighing between 180 g and 120 g, and they were put on the laboratory diet. Initially, the baseline normal blood urea nitrogen (BUN) and serum creatinine levels were determined by sero-chemical examination from the blood sample of the albino rats taken out from the tail vein of the animal. Normal level of BUN is 15-21 mg/dl and serum creatinine is 0.2-0.8 mg/dl for albino rats.

Amikacin is available in parenteral form and contains 100 mg of amikacin in 2 ml (AMICIP) strength (AMICIP, Cipla). Normal saline was used for making the required strength of the drug.

Cefotaxime is available as (TAXIMAX, Alkem Lab) in vial and contains 1 g of drug per vial and is diluted in water for injection for making the required strength of the drug.
Freshly prepared normal saline and drug solution were injected intraperitoneally in the abdomen of albino rats. In strength of 15 mg/kg/day in two divided doses, amikacin on the first day of the experiment was injected; the blood was withdrawn from the tail of albino rat and was subjected for sero-chemical examination to determine the blood urea and serum creatinine levels after 6 hrs of giving the injection. In the similar manner, cefotaxime at a dose of 100 mg/kg/day in 2-3 divided dose was also administered in the various sets of the animals and were also subjected to the sero-chemical examinations to determine the blood urea and serum creatinine levels.

Albino rats were divided into four Groups, A, B, C, and D. Ten albino rats were included in each group.

Group A (control group): Received i.p. injection of normal saline in strength of 2 ml/kg/day in two divided doses for 4 weeks.

Group B (amikacin group): Received i.p. injection of amikacin in strength of 15 mg/kg/day in two divided doses for 4 weeks.

Group C (cefotaxime group): Received i.p. injection of cefotaxime in strength of 100 mg/kg/day in two divided doses for 4 weeks.

Group D (amikacin + cefotaxime): Received amikacin (15 mg/kg/day) + cefotaxime (100 mg/kg/day) in two divided doses for 4 weeks.

Recommended drug and doses were given daily up to 4 weeks in respective groups. Estimation of BUN and serum creatinine was done from the blood withdrawn from tails of albino rats. The sero-chemical tests were done for the first 2 weeks after daily injections of the test drugs i.e. with recommended dose of normal saline, amikacin, cefotaxime, and amikacin plus the cefotaxime. For the first 2 weeks, daily estimation of the BUN and serum creatinine was done. Thereafter, sero-chemical test was done at fortnightly interval for 6 months and then monthly interval for next 12 months during follow-up.

In this study, estimation of BUN and serum creatinine at 1st day, 14th day, and 28th day during i.p. injection and at 6th month and 18th month during follow-up were considered.

**Statistical analysis**

The results were charted in tabular form. Data obtained were expressed as mean±standard deviation and analyzed using the analysis of variance.

**RESULTS**

In Table 1 (Group A/control group) indicated that the mean level BUN and serum creatinine were within normal limits during i.p. administration of normal saline as well as during follow-up. This result was similar to the results plotted by Cohen et al. 1975.

In Table 2 (Group B), increase in mean BUN was seen which was highly significant during i.p. administration of amikacin (at 14th and 28th day). Decrease in mean BUN was seen during follow-up (at 6th and 18th month) but its mean level remained above the normal range for albino rat. Increase in mean serum creatinine was significant during i.p. administration of amikacin (at 14th and 28th day). Decrease in mean serum creatinine was seen during follow-up (at 6th and 18th month) and its mean level came to the normal range at 6th and 18th month.

In Table 3 (Group C), increase in mean BUN was seen which was highly significant during i.p. administration of cefotaxime (at 14th and 28th day). Decrease in mean BUN was seen during follow-up (at 6th and 18th month) but its mean level remained above the normal range for albino rat. Increase in mean serum creatinine was highly significant during i.p. administration of cefotaxime (at 14th and 28th day). Decrease in mean serum creatinine was seen during follow-up (at 6th and 18th month) and its mean level came to the normal range at 6th and 18th month.

In Table 4 (Group D), increase in mean BUN was seen which was highly significant during i.p. administration of amikacin plus cefotaxime (at 14th and 28th day). Decrease in mean BUN was seen during follow-up (at 6th and 18th month), but its level remained above the normal range. Increase in mean serum

Table 1: Effect of i.p. injection of normal saline (Group A/control group) on BUN and serum creatinine in experimental albino rats.

|          | BUN          | Serum creatinine |
|----------|--------------|-----------------|
|          | Mean | SD  | SEM | t value | p value | Mean | SD | SEM | t value | p value |
| 1st day  | 20.37 | 0.08 | 0.026 | -       | -       | 0.50 | 0.067 | 0.021 | -       | -       |
| 14th day | 20.42 | 0.10 | 0.033 | 1.23    | >0.05   | 0.49 | 0.096 | 0.031 | 0.37    | >0.05   |
| 28th day | 20.48 | 0.09 | 0.029 | 1.47    | >0.05   | 0.48 | 0.075 | 0.024 | 0.27    | >0.05   |
| 6th month| 20.38 | 0.10 | 0.033 | 2.45    | >0.05   | 0.49 | 0.034 | 0.011 | 0.13    | >0.05   |
| 18th month| 20.45 | 0.07 | 0.022 | 1.72    | >0.05   | 0.48 | 0.045 | 0.014 | 0.30    | >0.05   |

SD: Standard deviation, SEM: Standard error mean, BUN: Blood urea nitrogen

Ahmad S et al. Int J Basic Clin Pharmacol. 2015 Apr;4(2):224-229
creatinine was highly significant during i.p. administration of amikacin plus cefotaxime (at 14th and 28th day). Decrease in mean serum creatinine was seen during follow-up (at 6th and 18th month), but its mean level remained above the normal range.

DISCUSSION

Noone et al., 1973 put forward comments about the work of Prof. Fillastre et al. (1973) that acute renal failure occurred during the treatment with high doses of amikacin and other cephalosporins combination. Schultz et al., 1971 described six patients developing acute renal failure which was attributed by an aminoglycoside and cephalosporins therapy combination simultaneously. However, with continuous therapy even in those patients with normal renal function, the same do se may lead to gradually increasing serum concentration of creatinine and blood urea, particularly after 7-10 days. Continuous laboratory monitoring is essential for detecting this trend so that dosage may be modified.

Interaction between amikacin and cephalothin as a cause of acute renal failure has been reported by Tvedegaard. According to him, interaction of amikacin and cephalosporins may be nephrotoxic even in therapeutic doses. A patient with normal serum creatinine, when treated with this combination of antibiotics in the indicated dose, creatinine clearance falls after 5 days. However, when the alleged drugs were withdrawn, creatinine clearance improved slowly.

Acute renal failure with combined amikacin and cephalosporin therapy had also been reported by Fillastre et al. Three patients with normal renal function developed acute renal failure between the 9th and 27th day of combined amikacin and a cephalosporin therapy. The nephrotoxicity

|          | BUN          | Serum creatinine          |
|----------|--------------|---------------------------|
|          | Mean | SD    | SEM | t value | p-value | Mean | SD | SEM | t value | p-value |
| 1st day  | 20.31 | 0.06  | 0.018 | - | - | 0.50 | 0.07 | 0.022 | - | - |
| 14th day | 24.08 | 0.50  | 0.157 | 22.39 | <0.001 | 0.65 | 0.093 | 0.029 | 4.18 | <0.01 |
| 28th day | 25.68 | 0.57  | 0.179 | 9.50 | <0.001 | 0.78 | 0.097 | 0.031 | 3.54 | <0.01 |
| 6th month| 22.60 | 0.09  | 0.030 | 18.30 | <0.001 | 0.63 | 0.08 | 0.025 | 4.07 | <0.01 |
| 18th month| 21.52 | 0.36  | 0.113 | 6.41 | <0.001 | 0.56 | 0.063 | 0.02 | 1.95 | >0.05 |

SD: Standard deviation, SEM: Standard error mean, BUN: Blood urea nitrogen

|          | BUN          | Serum creatinine          |
|----------|--------------|---------------------------|
|          | Mean | SD    | SEM | t value | p-value | Mean | SD | SEM | t value | p-value |
| 1st day  | 20.11 | 0.06  | 0.02 | - | - | 0.52 | 0.073 | 0.023 | - | - |
| 14th day | 23.84 | 0.08  | 0.03 | 16.64 | <0.001 | 0.69 | 0.063 | 0.02 | 5.80 | <0.001 |
| 28th day | 25.11 | 0.46  | 0.12 | 5.67 | <0.001 | 0.83 | 0.081 | 0.026 | 4.67 | <0.001 |
| 6th month| 22.50 | 0.78  | 0.25 | 11.64 | <0.001 | 0.69 | 0.062 | 0.02 | 4.67 | <0.001 |
| 18th month| 21.14 | 0.65  | 0.21 | 6.07 | <0.001 | 0.57 | 0.052 | 0.016 | 4.13 | <0.01 |

SD: Standard deviation, SEM: Standard error mean, BUN: Blood urea nitrogen

|          | BUN          | Serum creatinine          |
|----------|--------------|---------------------------|
|          | Mean | SD    | SEM | t value | p-value | Mean | SD | SEM | t value | p-value |
| 1st day  | 20.70 | 1.55  | 0.49 | - | - | 0.53 | 0.045 | 0.014 | - | - |
| 14th day | 26.32 | 1.1   | 0.35 | 9.89 | <0.001 | 0.90 | 0.084 | 0.027 | 10.30 | <0.001 |
| 28th day | 29.90 | 0.98  | 0.31 | 6.3 | <0.001 | 1.04 | 0.14 | 0.044 | 3.67 | <0.01 |
| 6th month| 26.05 | 1.6   | 0.50 | 6.78 | <0.001 | 0.91 | 0.045 | 0.014 | 3.59 | <0.01 |
| 18th month| 23.44 | 1.0   | 0.31 | 6.4 | <0.001 | 0.89 | 0.048 | 0.016 | 1.72 | <0.01 |

SD: Standard deviation, SEM: Standard error mean, BUN: Blood urea nitrogen
was of the tubule-interstitial type and the clinical picture was similar to that seen in acute drug-induced nephropathies. In these cases, high IV doses of amikacin combined with cephalosporins were probably nephrotoxic. The existing renal failure is aggravated, and there is a noticeable rise in blood urea level.  

Anuria and acute tubular necrosis associated with amikacin and cephalothin has been described. A patient developed acute tubular necrosis following treatment with cephalothin and amikacin, although other antibiotics e.g. amphotericin B, bacitracin, cephalosporins, and aminoglycosides have also been implicated.

It is impossible to determine in the single case whether one of the antibiotics independently is responsible for the nephrotoxicity or whether there is a synergistic nephrotoxic effect of the combination.

Combination antibiotic therapy is nephrotoxic and has been concluded by various studies. Several other workers have similar views on the combination of amikacin with cefotaxime.

The combination of amikacin with cefotaxime may prove to be nephrotoxic to the patients. These drug combinations must be prescribed carefully in a patient especially when the kidney function is compromised, and renal dysfunction is present.

CONCLUSION

Rise in BUN and serum creatinine was highly significant when the amikacin was combined with cefotaxime during i.p. administration as well as during follow-up. It concluded that these drug combinations may be harmful to the kidney, and gradually it can lead to permanent renal damage.

ACKNOWLEDGMENTS

We express our thanks to all faculties and staffs of Department of Pharmacology, PMCH, Patna for their valuable support. We also acknowledge technical staffs of Department of Biochemistry for their technical assistance.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Noone P, Pattison JR, Shafi MS. Acute renal failure after high doses of gentamicin and cephalothin. Lancet. 1973;1(7816):1387-8.
2. Tune BM, Fravert D. Cephalosporin nephrotoxicity. Transport, cytotoxicity and mitochondrial toxicity of cephaloglycin. J Pharmacol Exp Ther. 1980;215(1):186-90.
3. Bennett WM, Singer I, Coggins CJ. A guide to drug therapy in renal failure. JAMA. 1974;230(11):1544-53.
4. Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, et al. Drug therapy in renal failure: dosing guidelines for adults. Part I: antimicrobial agents, analgesics. Ann Intern Med. 1980;93(1):62-89.
5. Luft FC, Kleit SA. Renal parenchymal accumulation of aminoglycoside antibiotics in rats. J Infect Dis. 1974;130(6):656-9.
6. Luft FC, Patel V, Yum MN, Kleit SA. Nephrotoxicity of cephalosporin-gentamicin combinations in rats. Antimicrob Agents Chemother. 1976;9(5):831-9.
7. Bobrow SN, Jaffe E, Young RC. Anuria and acute tubular necrosis associated with gentamicin and cephalothin. JAMA. 1972;222(12):1546-7.
8. Schultzle RG, Winters RE, Kauffman H. Possible nephrotoxicity of gentamicin. J Infect Dis. 1971;124 Suppl: S145-7.
9. Fillastre JP, Laumonier R, Humbert G, Dubois D, Metayer J, Delpach A, et al. Acute renal failure associated with combined gentamicin and cephalothin. Br Med J. 1973;2(5863):396-7.
10. Noone P, Parsons TM, Pattison JR, Slack RC, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974;1(5906):477-81.
11. Klastersky J, Henri A, Hensgens C, Daneau D. Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. JAMA. 1974;227(1):45-8.
12. Klastersky J, Debusscher L, Weerts-Ruhl D, Prevost JM. Carbenicillin, cefazolin, and amikacin as an empiric therapy for febrile granulocytopenic cancer patients. Cancer Treat Rep. 1977;61(8):1433-9.
13. Klastersky J, Cappel R, Daneau D. Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer. 1973;31(2):331-6.
14. Klastersky J. Treatment of severe infections in patients with cancer. The role of new acyl-penicillins. Arch Intern Med. 1982;142:1984-7.
15. Cohen B, Saginur R, Cleenber J, Mendelson J, Kavalec E. Double-blind comparative trial of once – versus twice-daily netilmicin therapy in severe acute urinary tract infections. Curr Ther Res. 1985;38(6):880-4.
16. Kosek IC, Mazze RJ, Cousins MJ. Nephrotoxicity of gentamicin. Lab Invest. 1974;30(1):48-57.
17. Neu HC, Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1980;21(1):11-8.
18. Bailey RR. Renal failure in combined gentamicin and cephalothin therapy. Br Med J. 1973;2:776.
19. Kucers A, McK Bennett N. The Use of Antibiotics. 3rd edition. Public Health. 1980;94(3):206-7.
20. Klastersky J, Hensgens C, Debusscher L. Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother. 1975;7(5):640-5.
21. Craig WA, Welling PG, Jackson TC, Kunin CM. Pharmacology of cephalazin and other cephalosporins in patients with renal failure. J Infect Dis. 1973;128:347-53.
22. Barza M. The nephrotoxicity of cephalosporins: an overview. J Infect Dis 1978;137 Suppl: S60-73.
23. Child KJ, Dodds MG. Mechanism of urinary excretion of
cephaloridine and its effects on renal function in animals. Br J Pharmacol Chemother 1966;26(1):108-19.
24. Atkinson RM, Currie JP, Davis B, Pratt DA, Sharpe HM, Tomich EG. Acute toxicity of cephaloridine, an antibiotic derived from cephalosporin C. Toxicol Appl Pharmacol. 1966;8(3):398-406.
25. Kleinknecht D, Jungers P, Fillastre JP. Letter: nephrotoxicity of cephaloridine. Ann Intern Med. 1974;80(3):421-2.
26. Burland WL, Simpson K, Samuel PD. Combining cephaloridine and streptomycin for the treatment and prophylaxis of neonatal infections. Postgrad Med J. 1970;Suppl:85-9.
27. Harrison WO, Silverblatt FJ, Turck M. Gentamicin nephrotoxicity: failure of three cephalosporins to potentiate injury in rats. Antimicrob Agents Chemother. 1975;8(2):209-15.
28. Cohen L, Lapkin R, Kaloyanides GJ. Effect of gentamicin on renal function in the rat. J Pharmacol Exp Ther. 1975;193(1):264-73.
29. Tvedegaard E. Letter: interaction between gentamicin and cephalothin as cause of acute renal failure. Lancet. 1976;2(7985):581.
30. Benveniste R, Davies J. R-factor mediated gentamicin resistance: a new enzyme which modifies aminoglycoside antibiotics. FEBS Lett. 1971;14(5):293-96.
31. Burton JR, Lichtenstein NS, Colvin RB, Hyslop NE Jr. Acute renal failure during cephalothin therapy. JAMA. 1974;229:679-82.
32. Flandre O, Damon M. Experimental Study of Nephrotoxicity of Gentamicin in Rats, First International Symposium on Gentamicin, Basel, Schwabe and Co; 1967. p. 47-61.
33. Fanning WL, Gump D, Jick H. Gentamicin- and cephalothin-associated rises in blood urea nitrogen. Antimicrob Agents Chemother. 1976;10(1):80-2.
34. Opitz A, Herrmann I, van Herrath D, Schaefer K. Acute renal failure following gentamicin-cephalosporin association therapy. Med Welt. 1971;11:434-8.
35. Hansen MM, Kaaber K. Nephrotoxicity in combined cephalothin and gentamicin therapy. Acta Med Scand. 1977;201(5):463-7.